About
Ousia ['usja], from Greek; "essence"-Ousia Pharma arose from a unique discovery in academia and was quickly transformed into a biotechnology company. Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates for the benefit of patients with metabolic and cognitive disorders.
Who are we?
Ousia Pharma ApS is a Danish biotech start-up focused on the development of novel peptide-drug conjugates for the treatment of cognitive disorders and metabolic diseases. We utilize a targeting approach in which peptides are used to deliver modulators of synaptic plasticity to the brain.
The Team
Anders Bue Klein
Co-Founder, CEO, PhD in neuroscience Anders Bue Klein has a strong background in molecular metabolism and pharmocology with an impressive academic track record and has previously held an Assistant Professor position at the NNF Center for Basic Metabolic Research
Christoffer Clemmensen
Co-Founder, CSO, PhD in metabolism, Group Leader (Clemmensen Lab) Christoffer Clemmensen leads an academic laboratory at the NNF Center for Basic Metabolic Research and has held various international positions at highly ranked research institutions
Jonas O. Petersen
Co-Founder, COO, PhD in medicinal chemistry Besides his PhD in medicinal chemistry, Jonas O. Petersen holds a Master of Engineering in Advancend Chemistry
Board of Directors
Ian Laquian
Chairman of the Board, MSc, MBA, serial entrepreneur, Kariya, Lophora, Avilex
Mikael Thomsen
PhD in endocrinology, serial entrepreneur (e.g. Kariya, Lophora, Avilex)
Jeppe R. Andersen
MSc, MBA, CEO at Sanos
Morten Toft
MSc, HD-R, CFO at Green2x
Mission
We are dedicated to developing effective and safe pharmacotherapies to improve the health and lives of people living with metabolic and cognitive disorders
Pipeline
.png)